Articles from CTMC

CTMC, a joint venture between Resilience and MD Anderson Cancer Center, has entered into a collaborative partnership with Einstein Hospital Israelita in Sao Paulo, Brazil, aimed at accelerating the adoption of cell therapy in Brazil and all of Latin America.

CTMC, a joint venture between Resilience and MD Anderson Cancer Center, has appointed Amy Hay as Chief Business Officer and Duane Avant as Chief Technical Officer. The appointments are part of CTMC’s strategic growth plans to expand its support of novel cell therapy development.

CTMC, a joint venture between MD Anderson Cancer Center and Resilience, has entered a partnership with Syenex to advance the scalability and efficiency of engineered T cell therapies. Through this collaboration, CTMC will gain access to Syenex’s bioengineering systems, which provide a significant improvement in gene delivery efficiency and engineering timelines.

CTMC, a joint venture between MD Anderson Cancer Center and Resilience, celebrates one year since its founding to accelerate life-saving cell therapies reaching patients. During its first year, CTMC has partnered with MD Anderson investigators and biotech companies to bring several novel cell therapies through Investigational New Drug (IND)-enabling studies and U.S. Food and Drug Administration (FDA) interactions to initiate clinical development.

CTMC, a joint venture between Resilience + MD Anderson Cancer Center, announces that it has been awarded $9.1M in the newly created Cancer Prevention & Research Institute of Texas (CPRIT) Texas New Technologies Company grant. The grant will focus on retroviral vector (RVV) manufacturing, an enhanced tumor-infiltrating lymphocytes (TIL) platform, and a differentiated process development approach to CAR-T manufacturing.